written on 24.04.2014

BMS extends deal with Samsung as its pipeline percolates with more biologics


With a host of biologic products in its pipeline, Bristol-Myers Squibb sees the need for more capacity for making large-molecule drugs and has decided to build on a relationship it already has with South Korea's Samsung BioLogics.